Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience

Simple item page
dc.contributor.authorGemici A.
dc.contributor.authorAydogdu I.
dc.contributor.authorTerzi H.
dc.contributor.authorSencan M.
dc.contributor.authorAslan A.
dc.contributor.authorKaya A.H.
dc.contributor.authorDal M.S.
dc.contributor.authorAkay M.O.
dc.contributor.authorDogu M.H.
dc.contributor.authorAyyildiz O.
dc.contributor.authorSahin F.
dc.contributor.authorCagliyan G.A.
dc.contributor.authorYilmaz M.
dc.contributor.authorGokgoz Z.
dc.contributor.authorBilen Y.
dc.contributor.authorDemir C.
dc.contributor.authorSevindik O.G.
dc.contributor.authorKorkmaz S.
dc.contributor.authorEser B.
dc.contributor.authorAltuntas F.
dc.date.accessioned2024-07-22T08:10:01Z
dc.date.available2024-07-22T08:10:01Z
dc.date.issued2018
dc.description.abstractNodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5 years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46 months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses. Copyright © 2017 John Wiley & Sons, Ltd.
dc.identifier.DOI-ID10.1002/hon.2460
dc.identifier.issn02780232
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15056
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Ltd
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectFemale
dc.subjectHodgkin Disease
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectYoung Adult
dc.subjectbleomycin
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectcyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
dc.subjectcytarabine
dc.subjectdacarbazine
dc.subjectdexamethasone
dc.subjectdoxorubicin
dc.subjectetoposide
dc.subjectifosfamide
dc.subjectlactate dehydrogenase
dc.subjectrituximab
dc.subjectvinblastine
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectautologous stem cell transplantation
dc.subjectcancer combination chemotherapy
dc.subjectcancer immunotherapy
dc.subjectcancer recurrence
dc.subjectcancer regression
dc.subjectcancer staging
dc.subjectcancer therapy
dc.subjectchemoradiotherapy
dc.subjectclinical article
dc.subjectfemale
dc.subjectfollow up
dc.subjecthistology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectmale
dc.subjectmonotherapy
dc.subjectnodular lymphocyte predominant Hodgkin lymphoma
dc.subjectoverall survival
dc.subjectpriority journal
dc.subjectretrospective study
dc.subjectsalvage therapy
dc.subjectadolescent
dc.subjectclinical trial
dc.subjectHodgkin disease
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectyoung adult
dc.titleNodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
dc.typeArticle

Files

Collections

Scopus Koleksiyonu